|
PSI launched a proof-of-concept study of a novel biological agent in pediatric cancer patients. [Read More]
|
|
|
|
|
|
PSI initiated enrollment in proof-of-concept study of a novel influenza vaccine. [Read More]
|
|
|
|
|
|
|
PSI launched a phase III study of a novel product for the treatment of sepsis. [Read More]
|
|
|
|
|
|
|
PSI met an interim enrollment milestone of 200 randomized pediatric patients in a phase III study of a novel antiemetic used for the prevention of chemotherapy-induced nausea and vomiting (CINV). [Read More]
|
|
|
|
|
|
|
PSI launched a proof-of-concept study of a novel biological agent in patients with gastric cancer. [Read More]
|
|
|
|
|
|
|
PSI launched a phase III study of a novel antibiotic in patients with community-acquired bacterial pneumonia (CABP). [Read More]
|
|
|
|
|
|
PSI met an interim enrollment milestone of 150 randomized patients in a phase II study of a novel antineoplastic agent in metastatic non-small cell lung cancer (NSCLC). [Read More]
|
|
|
|
|
|
|
PSI reached an interim enrollment milestone of 50 randomized patients in a phase III study of a novel antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI). [Read More]
|
|
|
|
|
|
|
PSI reached an interim enrollment milestone of 150 randomized pediatric patients in a phase III study of a novel antiemetic used for the prevention of chemotherapy-induced nausea and vomiting (CINV). [Read More]
|
|
|
|
|
|
|
PSI initiated enrollment in a phase II study of a novel biological agent in non-small cell lung cancer (NSCLC). [Read More]
|
|
|
|
|
|
PSI initiated enrollment in a phase II study of a novel supportive care product in patients with metastatic colorectal cancer (CRC). [Read More]
|
|
|
|
|
|
|
PSI met an interim enrollment milestone of 150 randomized patients in a phase II study of a novel biological agent in psoriasis. [Read More]
|
|
|
|
|
|
|
PSI met an interim enrollment objective of 50 randomized patients of a novel biological agent in relapsing-remitting multiple sclerosis. [Read More]
|
|
|
|
|
|
|
PSI met an interim enrollment milestone of 550 randomized pediatric patients in a phase III study of a novel antiemetic used for the prevention of postoperative nausea and vomiting (PONV). [Read More]
|
|
|
|
|
|
PSI reached an interim enrollment objective of 100 randomized pediatric patients in a phase III study of a novel antiemetic used for the prevention of chemotherapy-induced nausea and vomiting (CINV). [Read More]
|
|
|
|
|
|
|
PSI reached an interim enrollment target of 150 randomized patients in a phase II study of a novel antineoplastic agent in pancreatic cancer. [Read More]
|
|
|
|
|
|
|
PSI launched a phase II study of a novel diagnostic agent in patients with prostate cancer. [Read More]
|
|
|
|
|
|
|
PSI completed the active treatment period in a phase II study of a novel biological agent in patients with asthma. [Read More]
|
|
|
|
|
|
PSI launched a phase III study of a novel antibiotic in patients with community-acquired pneumonia (CAP). [Read More]
|
|
|
|
|
|
|
PSI initiated enrollment in a phase III study of a novel dialysis product in patients with chronic kidney disease (CKD). [Read More]
|
|
|
|
|
|
|
PSI met an interim enrollment milestone of 200 randomized patients in a phase III study of a novel biological agent in renal cell carcinoma. [Read More]
|
|
|
|
|
|
|
PSI initiated enrollment in a phase III study of a novel antineoplastic product in patients with metastatic colorectal cancer. [Read More]
|
|
|
|
|
|
PSI met an interim enrollment milestone of 300 randomized pediatric patients in a phase III study of a novel antiemetic used for the prevention of postoperative nausea and vomiting (PONV). [Read More]
|
|
|
|
|
|
|
PSI met an interim enrollment milestone of 50 randomized patients in a phase II study of a novel antibiotic for the treatment of complicated urinary tract infections (cUTI). [Read More]
|
|
|
|
|
|
|
PSI launched a phase III study of a novel biological agent in patients with gout. [Read More]
|
|
|
|
|
|
|
PSI initiated enrollment in a phase II study of a novel biological agent in patients with metastatic NSCLC. [Read More]
|
|
|
|
|
|
PSI met an interim enrollment target of 50 randomized patients in a phase II study of a novel biological agent in hepatocellular carcinoma (HCC). [Read More]
|
|
|
|
|
|
|
PSI initiated enrollment in a phase III study of a novel biological agent in patients with relapsing-remitting multiple sclerosis. [Read More]
|
|
|
|
|
|
|
PSI met an interim enrollment milestone of 200 randomized patients in a phase III study of a novel biological agent for the treatment of multiple myeloma. [Read More]
|
|
|
|
|
|
|
PSI initiated enrollment in a phase II study of a novel antineoplastic agent in patients with pancreatic cancer. [Read More]
|
|
|
|
|
|
|
PSI met an interim enrollment target of 100 randomized patients in a phase II novel combination product in asthma. [Read More]
|
|
|
|
|
|
PSI completed enrollment in a phase III study of a novel antineoplastic agent in patients with advanced ovarian cancer. [Read More]
|
|
|
|
|
|
|
PSI completed a proof-of-principle study of a novel biological agent in patients with non-Hodgkin’s lymphoma (NHL). [Read More]
|
|
|
|
|
|
|
PSI completed a proof-of-principle study of a novel biological agent in patients with non-Hodgkin’s lymphoma (NHL). [Read More]
|
|
|
|
|
|
|
PSI met an interim enrollment target of 200 randomized patients in a phase II study of a novel product for the treatment of overactive bladder. [Read More]
|
|
|
|
|
|
PSI met an interim enrollment milestone of 500 randomized patients in a phase III study of a novel antineoplastic agent in ovarian cancer. [Read More]
|
|
|
|
|
|
|
PSI launched a phase III study of a novel cancer vaccine in patients with renal cell carcinoma (RCC). [Read More]
|
|
|
|
|
|
|
PSI completed the active treatment period in a phase III study of a novel biological agent in patients with advanced breast cancer. [Read More]
|
|
|
|
|
|
|
PSI initiated enrollment in a phase II study of a novel angiotensin receptor modulator in patients with congestive heart failure (CHF). [Read More]
|
|
|
|
|
|
|
PSI reached an interim enrollment target of 100 randomized patients in a phase III study of a novel dialysis product in chronic kidney disease. [Read More]
|
|
|
|
|
|
PSI completed a phase II study of a novel biological agent in patients with relapsing-remitting multiple sclerosis. [Read More]
|
|
|
|
|
|
|
PSI reached an interim enrollment target of 100 randomized patients in a phase III study of a novel biological agent in chronic myelogenous leukemia (CML). [Read More]
|
|
|
|
|
|
|
PSI initiated enrollment in a phase III study of a novel antiemetic in pediatric patients with postoperative nausea and vomiting. [Read More]
|
|
|
|
|
|
|
PSI reached an interim enrollment milestone of 150 randomized patients in a phase III study of a novel biological agent in Hodgkin’s lymphoma. [Read More]
|
|
|
|
|
|
PSI initiated enrollment in a phase II study of a novel biological agent in patients with psoriatic arthritis. [Read More]
|
|
|
|
|
|
|
PSI completed enrollment in a phase III study of a novel antiviral in patients with chronic hepatitis C. [Read More]
|
|
|
|
|
|
|
PSI reached an interim enrollment objective of 250 randomized patients in a phase III study of a novel biological agent in relapsing-remitting multiple sclerosis. [Read More]
|
|
|
|
|
|
|
PSI completed the active treatment period in a phase III study of a novel hormonal agent in patients with prostate cancer. [Read More]
|
|
|
|
|
|
PSI initiated enrollment in a phase II study of a novel antibiotic with complicated urinary tract infections. [Read More]
|
|
|
|
|
|
|
PSI met an interim enrollment target of 450 randomized patients in a phase III study of a novel antineoplastic agent in advanced ovarian cancer. [Read More]
|
|
|
|
|
|
|
PSI launched a phase III study of a novel antineoplastic agent in patients with metastatic head and neck cancer. [Read More]
|
|
|
|
|
|
|
PSI initiated enrollment in a phase III study of a novel dialysis product in patients with chronic kidney disease. [Read More]
|
|
|
|
|
|
|
PSI completed a phase II study of a novel biological agent in patients with Crohn’s disease. [Read More]
|
|
|
|
|
|
PSI completed the active treatment period in a phase III study of a novel biological agent in patients with advanced NSCLC. [Read More]
|
|
|
|
|
|
|
PSI completed a phase II study of a novel biological agent in patients with advanced breast cancer. [Read More]
|
|
|
|
|
|
|
PSI launched a phase II study of a novel antineoplastic agent in patients with advanced pancreatic cancer. [Read More]
|
|
|
|
|
|
|
PSI initiated enrollment in a phase II study of a novel biological agent in patients with metastatic hepatocellular carcinoma. [Read More]
|
|
|
|
|
|
|
PSI completed a phase III study of a novel cancer vaccine in patients with metastatic renal cell carcinoma. [Read More]
|
|
|
|
|
|
PSI launched a proof-of-concept study of a novel biological agent in patients with acute myeloid leukemia. [Read More]
|
|
|
|
|
|
|
PSI completed enrollment in a phase III study of a novel biological agent in patients with advanced breast cancer. [Read More]
|
|
|
|
|
|
|
PSI achieved an interim enrollment objective of 50 randomized patients in a phase III study of a novel biological agent in renal cell carcinoma. [Read More]
|
|
|
|
|
|
|
PSI completed the active treatment period in a phase III study of a novel biological agent in patients with metastatic breast cancer. [Read More]
|
|
|
|
|
|
PSI launched a phase IV study of a novel recombinant coagulation factor in patients with hemophilia. [Read More]
|
|
|
|
|
|
|
PSI reached an interim enrollment milestone of 400 randomized patients in a phase III study of a novel antineoplastic in advanced ovarian cancer. [Read More]
|
|
|
|
|
|
|
PSI launched a phase III study of a novel biological agent in patients with psoriasis. [Read More]
|
|
|
|
|
|
|
PSI completed a phase III study of a novel biological agent in patients with gout. [Read More]
|
|
|
|
|
